Advertisement

Journal of Cancer Education

, Volume 27, Issue 4, pp 670–675 | Cite as

The Development of a Peritoneal Surface Malignancy Program: a Tale of Three Hospitals

  • Umut SarpelEmail author
  • Marcovalerio Melis
  • Elliot Newman
  • H. Leon Pachter
  • Russell S. Berman
Article

Abstract

An increasing amount of evidence supports the use of cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) for the treatment of select patients with carcinomatosis. The care of such patients is optimal at centers where physicians with expertise in the recognition, treatment, and follow-up of carcinomatosis collaborate to manage issues particular to patients undergoing HIPEC. New Peritoneal Surface Malignancy Programs should be introduced to meet the growing interest in this field; however, there are few guidelines available on how to propose, develop, and safely implement them across different hospital models. A new Peritoneal Surface Malignancy Program was initiated at a large academic medical center affiliated with three hospital systems serving distinct patient populations: a private hospital, a public hospital, and a Veterans Affairs hospital. Ten groups were identified as playing key roles in program implementation. Program approval was successfully obtained at all three hospitals. The initial two-year experience included a total of 20 cases across the three sites. Six of these cases were aborted due to high tumor volume, most of which (4/6) were at the public hospital. No 30-day mortalities occurred. Hospitals vary significantly in their approval process and timeline for new Peritoneal Surface Malignancy Program development. Patient populations differ in their awareness of HIPEC as a therapeutic modality. Public hospitals may serve patient populations with more advanced disease presentations. Careful coordination by the surgical oncologist with ten key groups allows for the safe introduction of a complex procedure within varied hospital models.

Keywords

Cytoreductive surgery Heated intraperitoneal chemotherapy Carcinomatosis Program development 

Notes

Disclosures

The authors have no disclosures to report.

References

  1. 1.
    Glehen O, Osinsky D, Beaujard AC et al (2003) Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 12:729–739PubMedCrossRefGoogle Scholar
  2. 2.
    Bayon LG, Sugarbaker PH, Moreno SG et al (2003) Initiation of a Program in Peritoneal Surface Malignancy. Surg Oncol Clin N Am 12:741–753CrossRefGoogle Scholar
  3. 3.
  4. 4.
    Schmid K, Boettcher MI, Pelz JO, Meyer T, Korinth G et al (2006) Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. Eur J Surg Oncol 32(10):1222–1225PubMedCrossRefGoogle Scholar
  5. 5.
    Schmidt C, Moritz S, Rath S et al (2009) Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. J Surg Oncol 100(4):297–301PubMedCrossRefGoogle Scholar
  6. 6.
    Miao N, Pingpank JF, Alexander HR et al (2009) Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations. Ann Surg Oncol 16(2):334–344PubMedCrossRefGoogle Scholar
  7. 7.
    Gilly FN, Cotte E, Brigand C et al (2006) Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 32(6):597–601PubMedCrossRefGoogle Scholar
  8. 8.
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Colon Cancer, version 3.2012, available at nccn.orgGoogle Scholar
  9. 9.
    Verwaal VJ, Bruin S, Boot H et al (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432PubMedCrossRefGoogle Scholar
  10. 10.
    Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575–1581PubMedCrossRefGoogle Scholar
  11. 11.
    Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68PubMedCrossRefGoogle Scholar
  12. 12.
    Esquivel J, Elias D, Baratti D et al (2008) Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 98:263–267PubMedCrossRefGoogle Scholar
  13. 13.
    Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113(2):315–325PubMedCrossRefGoogle Scholar
  14. 14.
    Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Umut Sarpel
    • 1
    Email author
  • Marcovalerio Melis
    • 1
  • Elliot Newman
    • 1
  • H. Leon Pachter
    • 1
  • Russell S. Berman
    • 1
  1. 1.Department of SurgeryNew York University Langone Medical CenterNew YorkUSA

Personalised recommendations